Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Oncol. Oct 24, 2022; 13(10): 779-788
Published online Oct 24, 2022. doi: 10.5306/wjco.v13.i10.779
Table 1 Clinicodemographics and histologic features in 526 patients with colorectal adenocarcinoma (PanCancer Atlas)
Feature
Level
Number
MSS number
Age (yr), mean ± SD65.8 ± 13.065.4 ± 12.7
GenderFemale 252 (47.9%)218 (47.1%)
Male272 (51.7%)243 (52.5%)
Unknown2 (0.4%)2 (0.4%)
Histopathologic differentiationWell19 (3.6%)18 (3.9%)
Moderate381 (72.4%)351 (75.8%)
Poor114 (21.7%)83 (17.9%)
Unknown12 (2.3%)11 (2.4%)
Tumor location Left254 (48.3%)248 (53.6%)
Right197 (37.5%)149 (32.2%)
Left and right3 (0.6%)3 (6.5%)
Unknown72 (13.7%)63 (13.6%)
Tumor staging (pT)T118 (3.4%)17 (3.7%)
T294 (17.9%)83 (17.9%)
T3355 (67.5%)310 (67.0%)
T457 (10.8%)52 (11.2%)
TX2 (0.4%)2 (0.4%)
Nodal staging (pN)N0305 (58.0%)255 (55.1%)
N1128 (24.3%)120 (25.9%)
N290 (17.1%)85 (18.4%)
NX3 (0.6%)3 (6.5%)
Metastasis (pM)M0388 (73.8%)338 (73.0%)
M168 (12.9%)66 (14.3%)
MX70 (13.3%)59 (12.7%)
Lymphovascular invasionPresent178 (33.8%)157 (33.9%)
Absent230 (43.7%)202 (43.6%)
Unknown118 (22.4%)104 (22.5%)
EthnicityCaucasian273 (51.9%)236 (51.0%)
African-American60 (11.4%)51 (11.0%)
Asian12 (2.3%)11 (2.4%)
Unknown181 (34.4%)165 (35.6%)
SubtypeCIN328 (62.4%)
MSI63 (12.0%)
GS58 (11.0%)
POLE10 (1.9%)
Unknown57 (10.8%)
Total526463
Table 2 Genetic mutation types and numbers in FAT family genes in colorectal adenocarcinoma (PanCancer Atlas)
Gene
Missense mutation
Nonsense mutation
Splicing mutation
Frame shift deletion
Frame shift insertion
Inflame deletion
Total mutation
Mutation in Cadherin domains
FAT185523219848 (49.0%)
FAT2902351010164 (63.4%)
FAT31246052013755 (40.1%)
FAT41981901040230133 (57.8%)
Table 3 Association of clinicopathologic features with FAT somatic mutations in colorectal adenocarcinoma (PanCancer Atlas)
Clinicopathologic features
Mutated FAT genes
Wildtype FAT genes
P value
Mutated FAT genes (MSS)
Wildtype FAT genes (MSS)
P value
Mean age (mean ± SD)66.5 ± 12.965.3 ± 13.00.91265.6 ± 12.165.3 ± 12.9
Sex0.6890.825
Female98 (49.0%)154 (47.2%)67 (46.5%)151 (47.3%)
Male102 (51.0%)170 (52.1%)77 (53.5%)166 (52.0%)
Location < 0.001a0.038a
Left side65 (32.5%)181 (55.5%)70 (48.6%)178 (55.8%)
Right side102 (51.0)98 (30.1%)57 (39.6%)92 (28.8%)
pT stage0.0930.083
pT1-250 (25.0%)61 (18.7%)38 (26.4%)61 (19.1%)
pT3-4150 (75.0%)263 (80.7%)106 (73.6%)256 (80.3%)
pN stage0.005a0.079
pN0133 (66.5%)172 (52.8%)87 (60.4%)168 (52.7%)
pN144 (22.0%)84 (25.8%)39 (27.1%)81 (25.4%)
pN223 (11.5%)67 (20.6%)18 (12.5%)67 (21.0%)
pM stage0.006a0.038a
pM0153 (76.5%)235 (72.1%)110 (76.4%)228 (71.5%)
pM115 (7.5%)53 (16.3%)13 (9.0%)53 (16.6%)
Differentiation grade0.3320.172
G1-2145 (72.5%)255 (78.2%)117 (81.3%)252 (79.0%)
G347 (23.5%)67 (20.6%)20 (13.9%)63 (19.7%)
Subtype< 0.001a
CIN92 (46.0%)236 (72.4%)
MSI56 (28.0%)7 (2.1%)
GS25 (12.5%)33 (10.1%)
Lymphovascular invasion0.3130.516
Positive61 (30.5%)117 (35.9%)44 (30.6%)113 (35.4%)
Negative90 (45.0%)140 (42.9%)63 (43.8%)139 (43.6%)
Total200 (38.0%)326 (62.0%)144 (31.1%)319 (68.9%)